Common Side Effects of Bimzelx
Bimzelx (bimekizumab-bkzx) most often causes upper respiratory tract infections, like colds or sinus issues, affecting about 21% of patients in trials. Oral candidiasis (mouth or throat yeast infections) occurs in 13-14%, frequently requiring antifungal treatment. Headache hits 7-9%, and injection site reactions (redness, itching, pain) affect 4-7%.[1][2]
Serious Side Effects and Warnings
Serious infections, including tuberculosis, are possible due to immune suppression—screen for latent TB before starting. Inflammatory bowel disease (ulcerature colitis, Crohn's) has worsened or started in some users; monitor for new or increasing stomach pain, diarrhea, or blood in stool. Hypersensitivity reactions like severe rash or swelling can happen. Avoid live vaccines during treatment.[1][2][3]
Side Effects by Body System
- Infections: Besides respiratory and fungal, cellulitis or herpes infections reported rarely.
- Gastrointestinal: Diarrhea (3-5%), nausea.
- Skin: Rash, urticaria (1-3%).
- Musculoskeletal: Arthralgia (joint pain, 2-4%).
- Other: Fatigue, fever under 2%.[1][2]
Rates vary by condition treated (plaque psoriasis, psoriatic arthritis, axial spondyloarthritis); psoriasis trials showed higher candidiasis vs. placebo.[2]
How Long Do Side Effects Last?
Most resolve within weeks; infections may need antibiotics or antifungals. Injection reactions fade in days. Long-term data (up to 2.5 years) shows no new major risks, but monitor for IBD flares.[3]
Who Gets Side Effects Most?
Higher risk in those with infection history, IBD predisposition, or on other immunosuppressants. No major differences by age, sex, or race in trials, but real-world use may vary.[1][2]
Bimzelx vs. Other IL-17 Inhibitors
Compared to Cosentyx (secukinumab) or Taltz (ixekizumab), Bimzelx has similar infection rates but higher oral candidiasis (dual IL-17A/F block may increase fungal risk). Taltz shows more IBD signals.[3]
[1]: Bimzelx Prescribing Information, UCB, Inc. (FDA-approved label, 2023). https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/761185s000lbl.pdf
[2]: ClinicalTrials.gov summaries (BE VIVID, BE READY, BE COMPLETE trials).
[3]: European Medicines Agency (EMA) Bimzelx Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-informationen.pdf